MMRi64
Based on 1 Customer Validation
MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.42%
- CAS. Nr.: 430458-66-5
- Formel: C22H17Cl2N3O
- Molecular Weight:410.30
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-16271
Kevetrin hydrochloridep53 Activator -
HY-120373
MB710p53-Y220C Stabilizer -
HY-112780
UC2288P21 Attenuator -
HY-15676
IdasanutlinMDM2 Inhibitor -
HY-12296
NavtemadlinMDM2-p53 Interaction Inhibitor -
HY-18935
CBL0137FACT Inhibitor -
HY-101518
AlrizomadlinMDM2 Inhibitor -
HY-101266
MilademetanMDM2 Inhibitor -
HY-10959
RG7112MDM2 Antagonist -
HY-14714
NSC-207895p53 Activator -
HY-18986
SAR405838MDM2-p53 Interaction Inhibitor -
HY-152859
BrigimadlinMDM-2 Inhibitor
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.6 μM
Compound: MMRI64
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-Glo assay
|
[PMID: 39185935] |
| Huh-7 | CC50 |
>48.96 μM
Compound: GNF-Pf-4822
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
[PMID: 18579783] |
Chemical Information
-
CAS. Nr. 430458-66-5
-
Appearance Solid
-
Molecular Weight 410.30
-
Formel C22H17Cl2N3O
-
Color White to off-white
-
SMILES
OC1=C2N=CC=CC2=CC=C1C(C3=CC=CC(Cl)=C3Cl)NC4=NC=CC(C)=C4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (243.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4372 mL | 12.1862 mL | 24.3724 mL | 60.9310 mL |
| 5 mM | 0.4874 mL | 2.4372 mL | 4.8745 mL | 12.1862 mL | |
| 10 mM | 0.2437 mL | 1.2186 mL | 2.4372 mL | 6.0931 mL | |
| 15 mM | 0.1625 mL | 0.8124 mL | 1.6248 mL | 4.0621 mL | |
| 20 mM | 0.1219 mL | 0.6093 mL | 1.2186 mL | 3.0466 mL | |
| 25 mM | 0.0975 mL | 0.4874 mL | 0.9749 mL | 2.4372 mL | |
| 30 mM | 0.0812 mL | 0.4062 mL | 0.8124 mL | 2.0310 mL | |
| 40 mM | 0.0609 mL | 0.3047 mL | 0.6093 mL | 1.5233 mL | |
| 50 mM | 0.0487 mL | 0.2437 mL | 0.4874 mL | 1.2186 mL | |
| 60 mM | 0.0406 mL | 0.2031 mL | 0.4062 mL | 1.0155 mL | |
| 80 mM | 0.0305 mL | 0.1523 mL | 0.3047 mL | 0.7616 mL | |
| 100 mM | 0.0244 mL | 0.1219 mL | 0.2437 mL | 0.6093 mL |
MMRi64 Related Classifications
HY-123950 Related Classifications
Powered by Bioz